Continuous Glucose Monitoring (CGM) in an Underserved Population

Launched by TULANE UNIVERSITY · Aug 14, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how using a continuous glucose monitor (CGM)—a small device that tracks blood sugar levels throughout the day—can help people with type 2 diabetes who are on insulin injections. The study focuses on individuals who may have limited access to healthcare, including those who are uninsured or covered by Medicaid. Researchers hope this study will improve diabetes care and reduce health differences in these underserved communities. This is a smaller, initial study to see if this approach works well before trying it on a larger scale.

To be eligible, participants need to be adults between 18 and 75 years old with type 2 diabetes, have blood sugar levels that are not well controlled (measured by a test called HbA1c at 7.5% or higher), and must be taking at least one insulin injection daily. They should also be receiving care at local clinics in the New Orleans area and be able to understand English and give consent to join the study. People who already use CGM devices, have certain serious health problems, or are pregnant cannot participate. If you join, you can expect to use a CGM device to help monitor your blood sugar continuously, which may offer better insights and support for managing diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18-75 years
• • Type 2 diabetes mellitus
• • HbA1C ≥ 7.5%
• • At least on 1 insulin injection therapy daily
• • Patients established with primary care clinic or endocrinology clinic or diabetes clinics in the New Orleans and surrounding areas
• • Patients with Medicaid or free care or uninsured
• • Patients must be able to speak and understand English and be capable of providing informed consent to participate in the study
• Exclusion Criteria:
• • Type 1 diabetes mellitus
• • Currently on CGM or using insulin pump
• • Advanced renal disease or Estimated Glomerular Filtration Rate (eGFR) \<40
• • Serious co-morbidities which in the investigator's opinion, will make it challenging for patients to participate
• • The patient has been diagnosed with end-stage renal disease, is on dialysis, or has had a kidney transplant, Hemoglobinopathies, iron therapy or other condition that interferes with HbA1c measurement
• • Pregnant